PE02472014A1 - Anti-CD38 antibodies - Google Patents

Anti-CD38 antibodies

Info

Publication number
PE02472014A1
PE02472014A1 PE2013001487A PE0014872013A PE02472014A1 PE 02472014 A1 PE02472014 A1 PE 02472014A1 PE 2013001487 A PE2013001487 A PE 2013001487A PE 0014872013 A PE0014872013 A PE 0014872013A PE 02472014 A1 PE02472014 A1 PE 02472014A1
Authority
PE
Peru
Prior art keywords
seq id
anti
cd38
cdr1
cdr2
Prior art date
Application number
PE2013001487A
Other languages
Spanish (es)
Inventor
Kathleen Ann Elias
Gregoy Landes
Shweta Singh
Wouter Korver
Andrew Walling Drake
Mary Haak-Frendscho
Gyorgy Pal Snell
Vinay Bhaskar
Original Assignee
Takeda Pharmaceutical
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority to US201061428699P priority Critical
Priority to US201161470382P priority
Priority to US201161470406P priority
Priority to US201161485104P priority
Application filed by Takeda Pharmaceutical filed Critical Takeda Pharmaceutical
Publication of PE02472014A1 publication Critical patent/PE02472014A1/en

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K16/00Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/40Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against enzymes
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6835Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
    • A61K47/6871Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting an enzyme
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K16/00Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2896Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against molecules with a "CD"-designation, not provided for elsewhere
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/99Enzyme inactivation by chemical treatment
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K2039/505Medicinal preparations containing antigens or antibodies comprising antibodies
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/20Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/30Immunoglobulins specific features characterized by aspects of specificity or valency
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/30Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/33Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/30Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/50Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52Constant or Fc region; Isotype
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/50Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/50Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565Complementarity determining region [CDR]
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/70Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C07K2317/732Antibody-dependent cellular cytotoxicity [ADCC]
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/70Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C07K2317/734Complement-dependent cytotoxicity [CDC]
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/70Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/90Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Abstract

SE REFIERE A UN ANTICUERPO AISLADO QUE SE UNE ESPECIFICAMENTE A LA CD38 HUMANA ( SEQ ID NO: 1) Y CD38 DE CINOMOLGO ( SEQ ID NO:2) QUE COMPRENDE: i) UNA REGION VARIABLE DE CADENA PESADA QUE TIENE CDR1 QUE COMPRENDE LA SEQ ID NO: 3, SEQ ID NO: 13 ENTRE OTRAS; CONCERNS an isolated antibody that specifically binds TO CD38 HUMAN (SEQ ID NO: 1) and CD38 cynomolgus (SEQ ID NO: 2) comprising: i) a variable region heavy chain HAVING CDR1 comprising SEQ ID NO: 3, SEQ ID NO: 13 among others; CDR2 QUE COMPRENDE LA SEQ ID NO: 4, SEQ ID NO: 14, ENTRE OTRAS; CDR2 comprising SEQ ID NO: 4, SEQ ID NO: 14, among others; CDR3 QUE COMPRENDE LA SEQ ID NO: 5, SEQ ID NO: 15, ENTRE OTRAS. CDR3 comprising SEQ ID NO: 5, SEQ ID NO: 15, among others. ii) UNA REGION VARIABLE DE CADENA LIGERA QUE TIENE: CDR1 QUE COMPRENDE LA SEQ ID NO: 6, SEQ ID NO: 16, ENTRE OTRAS; ii) a variable light chain region having: CDR1 comprising SEQ ID NO: 6, SEQ ID NO: 16, INTER; CDR2 QUE COMPRENDE LA SEQ ID NO: 7, SEQ ID NO: 17, ENTRE OTRAS; CDR2 comprising SEQ ID NO: 7, SEQ ID NO: 17, among others; CDR3 QUE COMPRENDE LA SEQ ID NO: 8, SEQ ID NO: 18, ENTRE OTRAS. CDR3 comprising SEQ ID NO: 8, SEQ ID NO: 18, among others. TAMBIEN SE REFIERE A UNA COMPOSICION FARMACEUTICA Y ES UTIL PARA EL TRATAMIENTO DE ENFERMEDADES AUTOINMUNES. Also it relates to a pharmaceutical composition and is useful for the treatment of autoimmune diseases.
PE2013001487A 2010-12-30 2011-12-30 Anti-CD38 antibodies PE02472014A1 (en)

Priority Applications (4)

Application Number Priority Date Filing Date Title
US201061428699P true 2010-12-30 2010-12-30
US201161470382P true 2011-03-31 2011-03-31
US201161470406P true 2011-03-31 2011-03-31
US201161485104P true 2011-05-11 2011-05-11

Publications (1)

Publication Number Publication Date
PE02472014A1 true PE02472014A1 (en) 2014-03-12

Family

ID=45498158

Family Applications (1)

Application Number Title Priority Date Filing Date
PE2013001487A PE02472014A1 (en) 2010-12-30 2011-12-30 Anti-CD38 antibodies

Country Status (34)

Country Link
US (6) US8362211B2 (en)
EP (4) EP2658870B1 (en)
JP (6) JP6148984B2 (en)
KR (2) KR101945002B1 (en)
CN (2) CN107365385A (en)
AR (1) AR084747A1 (en)
AU (2) AU2011351921B2 (en)
BR (1) BR112013017009A2 (en)
CA (1) CA2822061A1 (en)
CO (1) CO6761368A2 (en)
CR (1) CR20130313A (en)
DK (2) DK2658871T3 (en)
EA (2) EA029303B1 (en)
EC (1) ECSP13012794A (en)
ES (2) ES2674175T3 (en)
GE (1) GEP20166493B (en)
HR (2) HRP20181176T1 (en)
HU (2) HUE038535T2 (en)
IL (1) IL226973A (en)
LT (2) LT2658871T (en)
MA (1) MA34763B1 (en)
MX (1) MX350903B (en)
MY (1) MY160499A (en)
NZ (2) NZ612272A (en)
PE (1) PE02472014A1 (en)
PL (2) PL2658871T3 (en)
RS (2) RS57526B1 (en)
SG (1) SG191211A1 (en)
SI (2) SI2658870T1 (en)
TR (1) TR201808709T4 (en)
TW (1) TWI564304B (en)
UY (1) UY33850A (en)
WO (2) WO2012092612A1 (en)
ZA (1) ZA201304696B (en)

Families Citing this family (60)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SI2511297T1 (en) 2004-02-06 2015-07-31 Morphosys Ag Anti-CD38 human antibodies and uses therefor
US9200061B2 (en) * 2004-02-06 2015-12-01 Morpho Sys AG Generation and profiling of fully human HuCAL gold®-derived therapeutic antibodies specific for human CD3i
US8088896B2 (en) 2005-10-12 2012-01-03 Morphosys Ag Generation and profiling of fully human gold-derived therapeutic antibodies specific for human CD38
CN103118706B (en) 2010-09-27 2016-05-18 莫佛塞斯公司 Anti-cd38 antibody lenalidomide or bortezomib for the treatment of multiple myeloma and nhl
TWI564304B (en) * 2010-12-30 2017-01-01 Takeda Pharmaceuticals Co Anti-cd38 antibodies
SG10201603411WA (en) 2011-10-28 2016-07-28 Teva Pharmaceuticals Australia Pty Ltd Polypeptide constructs and uses thereof
WO2014010586A1 (en) 2012-07-10 2014-01-16 武田薬品工業株式会社 Pharmaceutical preparation for injection
BR112015006731A2 (en) 2012-09-25 2017-07-04 Morphosys Ag combinations and uses thereof
BR112015012987A2 (en) * 2012-12-07 2017-09-12 Sanofi Sa compositions comprising anti-CD38 antibodies and lenalidomide
WO2014172371A2 (en) * 2013-04-16 2014-10-23 Genentech, Inc. Pertuzumab variants and evaluation thereof
UA113129C2 (en) * 2013-04-29 2016-12-12 CONSTRUCTION fused antibody against CD38 with poor interferon alfa-2b
US9963515B2 (en) 2013-04-29 2018-05-08 Teva Pharmaceuticals Australia Pty Ltd. Anti-CD38 antibodies and fusions to attenuated interferon alpha-2B
JP2016536314A (en) * 2013-10-31 2016-11-24 サノフイ Specific anti-cd38 antibody for the treatment of human cancer
JP2018501297A (en) * 2014-11-04 2018-01-18 グレンマーク ファーマシューティカルズ, エセ.アー. Cd3 / CD38 t cell retargeting heterodimer immunoglobulin and a manufacturing method thereof
EP3176185A1 (en) 2013-11-04 2017-06-07 Glenmark Pharmaceuticals S.A. Production of t cell retargeting hetero-dimeric immunoglobulins
JP2017506640A (en) * 2014-02-14 2017-03-09 セントローズ, エルエルシー Extracellular targeted drug conjugate
US9732154B2 (en) * 2014-02-28 2017-08-15 Janssen Biotech, Inc. Anti-CD38 antibodies for treatment of acute lymphoblastic leukemia
US9603927B2 (en) 2014-02-28 2017-03-28 Janssen Biotech, Inc. Combination therapies with anti-CD38 antibodies
WO2015142675A2 (en) 2014-03-15 2015-09-24 Novartis Ag Treatment of cancer using chimeric antigen receptor
CA2945902A1 (en) 2014-05-01 2015-12-03 Teva Pharmaceuticals Australia Pty Ltd Combination of lenalidomide or pomalidomide and cd38 antibody-attenuated interferon-alpha constructs, and the use thereof
WO2016014530A1 (en) 2014-07-21 2016-01-28 Novartis Ag Combinations of low, immune enhancing. doses of mtor inhibitors and cars
WO2016089960A1 (en) * 2014-12-04 2016-06-09 Janssen Biotech, Inc. Anti-cd38 antibodies for treatment of acute myeloid leukemia
US20180044424A1 (en) 2015-02-02 2018-02-15 Novartis Ag Car-expressing cells against multiple tumor antigens and uses thereof
CA2976696A1 (en) * 2015-02-17 2016-08-25 Millennium Pharmaceuticals, Inc. Combination therapy for cancer treatment
EP3280443A4 (en) * 2015-04-08 2018-12-26 Sorrento Therapeutics, Inc. Antibody therapeutics that bind cd38
EP3286211A1 (en) 2015-04-23 2018-02-28 Novartis AG Treatment of cancer using chimeric antigen receptor and protein kinase a blocker
CN108136218A (en) * 2015-05-20 2018-06-08 詹森生物科技公司 Anti-cd38 antibodies for treatment of light chain amyloidosis and other cd38-positive hematological malignancies
KR20180010259A (en) 2015-05-30 2018-01-30 몰레큘러 템플레이츠, 인코퍼레이션. De-immunization of a Shiga toxin subunit scaffold and cells comprising the same-targeting molecules
MX2018000265A (en) * 2015-06-22 2018-05-23 Janssen Biotech Inc Combination therapies for heme malignancies with anti-cd38 antibodies and survivin inhibitors.
US20160376373A1 (en) * 2015-06-24 2016-12-29 Janssen Biotech, Inc. Immune Modulation and Treatment of Solid Tumors with Antibodies that Specifically Bind CD38
US20180230193A1 (en) 2015-08-07 2018-08-16 Andreas Loew Treatment of cancer using chimeric cd3 receptor proteins
CN108603200A (en) 2015-11-23 2018-09-28 诺华股份有限公司 Optimized lentiviral transfer vectors and uses thereof
EP3423498A1 (en) 2016-03-04 2019-01-09 MorphoSys AG Clinical assessment of m-protein response in multiple myeloma
WO2017165683A1 (en) 2016-03-23 2017-09-28 Novartis Ag Cell secreted minibodies and uses thereof
WO2018002181A1 (en) * 2016-06-28 2018-01-04 Umc Utrecht Holding B.V. TREATMENT OF IgE-MEDIATED DISEASES WITH ANTIBODIES THAT SPECIFICALLY BIND CD38
WO2018013917A1 (en) * 2016-07-15 2018-01-18 Takeda Pharmaceutical Company Limited Methods and materials for assessing response to plasmablast- and plasma cell-depleting therapies
US20180021432A1 (en) 2016-07-20 2018-01-25 Hybrigenics Sa. Combinations of inecalcitol with an anti-cd38 agent and their uses for treating cancer
AU2017353427A1 (en) 2016-11-02 2019-05-16 Engmab Sàrl Bispecific antibody against BCMA and CD3 and an immunological drug for combined use in treating multiple myeloma
WO2018111340A1 (en) 2016-12-16 2018-06-21 Novartis Ag Methods for determining potency and proliferative function of chimeric antigen receptor (car)-t cells
WO2018144535A1 (en) 2017-01-31 2018-08-09 Novartis Ag Treatment of cancer using chimeric t cell receptor proteins having multiple specificities
WO2018160731A1 (en) 2017-02-28 2018-09-07 Novartis Ag Shp inhibitor compositions and uses for chimeric antigen receptor therapy
WO2018183376A1 (en) * 2017-03-28 2018-10-04 Rigel Pharmaceuticals, Inc. Acvr2a-specific antibody and method of use thereof
US20180312536A1 (en) 2017-04-14 2018-11-01 Solstice Biologics, Ltd. Immunomodulating polynucleotides, antibody conjugates thereof, and methods of their use
WO2019034752A1 (en) * 2017-08-16 2019-02-21 Tusk Therapeutics Ltd Cd38 modulating antibody
WO2018224683A1 (en) * 2017-06-08 2018-12-13 Tusk Therapeutics Ltd Cd38 modulating antibody
WO2018224682A1 (en) * 2017-06-08 2018-12-13 Tusk Therapeutics Ltd Cd38 modulating antibody
WO2018234370A1 (en) 2017-06-20 2018-12-27 Institut Curie Immune cells defective for suv39h1
WO2019055689A1 (en) 2017-09-13 2019-03-21 Teneobio, Inc. Heavy chain antibodies binding to ectoenzymes
WO2019074973A2 (en) * 2017-10-10 2019-04-18 Sanofi Anti-cd38 antibodies and methods of use
WO2019084288A1 (en) 2017-10-25 2019-05-02 Novartis Ag Methods of making chimeric antigen receptor-expressing cells
WO2019089798A1 (en) 2017-10-31 2019-05-09 Novartis Ag Anti-car compositions and methods
WO2019089832A1 (en) 2017-10-31 2019-05-09 Janssen Biotech, Inc. Methods of treating high risk multiple myeloma
WO2019090004A1 (en) 2017-11-01 2019-05-09 Juno Therapeutics, Inc. Process for producing a t cell composition
WO2019089855A1 (en) 2017-11-01 2019-05-09 Juno Therapeutics, Inc. Process for generating therapeutic compositions of engineered cells
WO2019089969A2 (en) 2017-11-01 2019-05-09 Juno Therapeutics, Inc. Antibodies and chimeric antigen receptors specific for b-cell maturation antigen
WO2019089858A2 (en) 2017-11-01 2019-05-09 Juno Therapeutics, Inc. Methods of assessing or monitoring a response to a cell therapy
WO2019090003A1 (en) 2017-11-01 2019-05-09 Juno Therapeutics, Inc. Chimeric antigen receptors specific for b-cell maturation antigen (bcma)
WO2019113557A1 (en) 2017-12-08 2019-06-13 Juno Therapeutics, Inc. Process for producing a composition of engineered t cells
WO2019113559A2 (en) 2017-12-08 2019-06-13 Juno Therapeutics, Inc. Phenotypic markers for cell therapy and related methods
WO2019113556A1 (en) 2017-12-08 2019-06-13 Juno Therapeutics, Inc. Serum-free media formulation for culturing cells and methods of use thereof

Family Cites Families (121)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3773919A (en) 1969-10-23 1973-11-20 Du Pont Polylactide-drug mixtures
US3691016A (en) 1970-04-17 1972-09-12 Monsanto Co Process for the preparation of insoluble enzymes
CA1023287A (en) 1972-12-08 1977-12-27 Boehringer Mannheim G.M.B.H. Process for the preparation of carrier-bound proteins
US4179337A (en) 1973-07-20 1979-12-18 Davis Frank F Non-immunogenic polypeptides
US4195128A (en) 1976-05-03 1980-03-25 Bayer Aktiengesellschaft Polymeric carrier bound ligands
US4330440A (en) 1977-02-08 1982-05-18 Development Finance Corporation Of New Zealand Activated matrix and method of activation
CA1093991A (en) 1977-02-17 1981-01-20 Hideo Hirohara Enzyme immobilization with pullulan gel
US4169888A (en) 1977-10-17 1979-10-02 The Upjohn Company Composition of matter and process
US4229537A (en) 1978-02-09 1980-10-21 New York University Preparation of trichloro-s-triazine activated supports for coupling ligands
US4307016A (en) 1978-03-24 1981-12-22 Takeda Chemical Industries, Ltd. Demethyl maytansinoids
US4256746A (en) 1978-11-14 1981-03-17 Takeda Chemical Industries Dechloromaytansinoids, their pharmaceutical compositions and method of use
JPS55102583A (en) 1979-01-31 1980-08-05 Takeda Chem Ind Ltd 20-acyloxy-20-demethylmaytansinoid compound
JPS55162791A (en) 1979-06-05 1980-12-18 Takeda Chem Ind Ltd Antibiotic c-15003pnd and its preparation
JPS6023084B2 (en) 1979-07-11 1985-06-05 Ajinomoto Kk
JPS6253158B2 (en) 1979-09-19 1987-11-09 Takeda Chemical Industries Ltd
EP0028683A1 (en) 1979-09-21 1981-05-20 Takeda Chemical Industries, Ltd. Antibiotic C-15003 PHO and production thereof
JPH0115514B2 (en) 1979-09-21 1989-03-17 Takeda Chemical Industries Ltd
WO1982001188A1 (en) 1980-10-08 1982-04-15 Takeda Chemical Industries Ltd 4,5-deoxymaytansinoide compounds and process for preparing same
US4450254A (en) 1980-11-03 1984-05-22 Standard Oil Company Impact improvement of high nitrile resins
US4315929A (en) 1981-01-27 1982-02-16 The United States Of America As Represented By The Secretary Of Agriculture Method of controlling the European corn borer with trewiasine
US4313946A (en) 1981-01-27 1982-02-02 The United States Of America As Represented By The Secretary Of Agriculture Chemotherapeutically active maytansinoids from Trewia nudiflora
JPH0114918B2 (en) 1981-05-20 1989-03-14 Takeda Chemical Industries Ltd
US4640835A (en) 1981-10-30 1987-02-03 Nippon Chemiphar Company, Ltd. Plasminogen activator derivatives
US4496689A (en) 1983-12-27 1985-01-29 Miles Laboratories, Inc. Covalently attached complex of alpha-1-proteinase inhibitor with a water soluble polymer
EP0206448B1 (en) 1985-06-19 1990-11-14 Ajinomoto Co., Inc. Hemoglobin combined with a poly(alkylene oxide)
US5776093A (en) 1985-07-05 1998-07-07 Immunomedics, Inc. Method for imaging and treating organs and tissues
US4970198A (en) 1985-10-17 1990-11-13 American Cyanamid Company Antitumor antibiotics (LL-E33288 complex)
US5057313A (en) 1986-02-25 1991-10-15 The Center For Molecular Medicine And Immunology Diagnostic and therapeutic antibody conjugates
AU597574B2 (en) 1986-03-07 1990-06-07 Massachusetts Institute Of Technology Method for enhancing glycoprotein stability
EP0271581B1 (en) 1986-04-17 1993-01-13 Kyowa Hakko Kogyo Co., Ltd. Novel compounds dc-88a and dc-89a1 and process for their preparation
US4791192A (en) 1986-06-26 1988-12-13 Takeda Chemical Industries, Ltd. Chemically modified protein with polyethyleneglycol
US4880935A (en) 1986-07-11 1989-11-14 Icrf (Patents) Limited Heterobifunctional linking agents derived from N-succinimido-dithio-alpha methyl-methylene-benzoates
US5606040A (en) 1987-10-30 1997-02-25 American Cyanamid Company Antitumor and antibacterial substituted disulfide derivatives prepared from compounds possessing a methyl-trithio group
US5770701A (en) 1987-10-30 1998-06-23 American Cyanamid Company Process for preparing targeted forms of methyltrithio antitumor agents
FI102355B (en) 1988-02-11 1998-11-30 Squibb Bristol Myers Co The method of connecting the spacer own the anthracycline immunoconjugate preparation of orthoformates to give
US5084468A (en) 1988-08-11 1992-01-28 Kyowa Hakko Kogyo Co., Ltd. Dc-88a derivatives
US5053394A (en) 1988-09-21 1991-10-01 American Cyanamid Company Targeted forms of methyltrithio antitumor agents
US5530101A (en) 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
JP2598116B2 (en) 1988-12-28 1997-04-09 協和醗酵工業株式会社 New substances dc113
US5187186A (en) 1989-07-03 1993-02-16 Kyowa Hakko Kogyo Co., Ltd. Pyrroloindole derivatives
JP2510335B2 (en) 1989-07-03 1996-06-26 協和醗酵工業株式会社 Dc-88a derivatives
CA2026147C (en) 1989-10-25 2006-02-07 Ravi J. Chari Cytotoxic agents comprising maytansinoids and their therapeutic use
US5208020A (en) 1989-10-25 1993-05-04 Immunogen Inc. Cytotoxic agents comprising maytansinoids and their therapeutic use
US5859205A (en) 1989-12-21 1999-01-12 Celltech Limited Humanised antibodies
WO1991017158A1 (en) 1990-05-07 1991-11-14 Scripps Clinic And Research Foundation Intermediates in the formation of the calicheamicin and esperamicin oligosaccharides
WO1994004679A1 (en) 1991-06-14 1994-03-03 Genentech, Inc. Method for making humanized antibodies
LU91067I2 (en) 1991-06-14 2004-04-02 Genentech Inc Trastuzumab and its variants and derivatives chemical immuno including immotoxines
US5264586A (en) 1991-07-17 1993-11-23 The Scripps Research Institute Analogs of calicheamicin gamma1I, method of making and using the same
US5622929A (en) 1992-01-23 1997-04-22 Bristol-Myers Squibb Company Thioether conjugates
DK0563475T3 (en) 1992-03-25 2000-09-18 Immunogen Inc Conjugates of cell binding agents and derivatives of CC-1065
ZA9302522B (en) 1992-04-10 1993-12-20 Res Dev Foundation Immunotoxins directed against c-erbB-2(HER/neu) related surface antigens
US5635483A (en) 1992-12-03 1997-06-03 Arizona Board Of Regents Acting On Behalf Of Arizona State University Tumor inhibiting tetrapeptide bearing modified phenethyl amides
JP3720353B2 (en) 1992-12-04 2005-11-24 メディカル リサーチ カウンシル Multivalent and multispecific binding proteins, their preparation and use
US5780588A (en) 1993-01-26 1998-07-14 Arizona Board Of Regents Elucidation and synthesis of selected pentapeptides
US6214345B1 (en) 1993-05-14 2001-04-10 Bristol-Myers Squibb Co. Lysosomal enzyme-cleavable antitumor drug conjugates
AU689131B2 (en) 1993-10-01 1998-03-26 Teikoku Hormone Mfg. Co., Ltd. Novel peptide derivative
PT705833E (en) 1994-04-22 2004-11-30 Kyowa Hakko Kogyo Kk Derived from dc-89
JPH07309761A (en) 1994-05-20 1995-11-28 Kyowa Hakko Kogyo Co Ltd Method for stabilizing duocamycin derivative
US5773001A (en) 1994-06-03 1998-06-30 American Cyanamid Company Conjugates of methyltrithio antitumor agents and intermediates for their synthesis
US5550246A (en) 1994-09-07 1996-08-27 The Scripps Research Institute Calicheamicin mimics
US5663149A (en) 1994-12-13 1997-09-02 Arizona Board Of Regents Acting On Behalf Of Arizona State University Human cancer inhibitory pentapeptide heterocyclic and halophenyl amides
US6086875A (en) 1995-01-17 2000-07-11 The Brigham And Women's Hospital, Inc. Receptor specific transepithelial transport of immunogens
US5712374A (en) 1995-06-07 1998-01-27 American Cyanamid Company Method for the preparation of substantiallly monomeric calicheamicin derivative/carrier conjugates
US5714586A (en) 1995-06-07 1998-02-03 American Cyanamid Company Methods for the preparation of monomeric calicheamicin derivative/carrier conjugates
JP2000503639A (en) 1995-12-22 2000-03-28 ブリストル―マイヤーズ スクイブ カンパニー Linker such branched hydrazone
DE122007000021I1 (en) 1997-04-07 2007-05-24 Genentech Inc Anti-VEFG Antibodies
EP2261229A3 (en) 1998-04-20 2011-03-23 GlycArt Biotechnology AG Glycosylation engineering of antibodies for improving antibody-dependent cellular cytotoxicity
US7425541B2 (en) 1998-12-11 2008-09-16 Medarex, Inc. Enzyme-cleavable prodrug compounds
US6737056B1 (en) 1999-01-15 2004-05-18 Genentech, Inc. Polypeptide variants with altered effector function
ES2418360T3 (en) 1999-04-09 2013-08-13 Kyowa Hakko Kirin Co., Ltd. Method for controlling the activity of a molecule immunofunctional
US6939545B2 (en) 1999-04-28 2005-09-06 Genetics Institute, Llc Composition and method for treating inflammatory disorders
EP1229934B1 (en) 1999-10-01 2014-03-05 Immunogen, Inc. Compositions and methods for treating cancer using immunoconjugates and chemotherapeutic agents
US7303749B1 (en) 1999-10-01 2007-12-04 Immunogen Inc. Compositions and methods for treating cancer using immunoconjugates and chemotherapeutic agents
AU7950400A (en) 1999-10-19 2001-04-30 Kyowa Hakko Kogyo Co. Ltd. Process for producing polypeptide
US6333410B1 (en) 2000-08-18 2001-12-25 Immunogen, Inc. Process for the preparation and purification of thiol-containing maytansinoids
AU9417501A (en) 2000-10-06 2002-04-22 Kyowa Hakko Kogyo Kk Method of purifying antibody
EP2314686B1 (en) 2000-10-06 2017-07-05 Kyowa Hakko Kirin Co., Ltd. Cells producing antibody compositions
IT1320715B1 (en) 2000-10-19 2003-12-10 Cselt Centro Studi Lab Telecom Form generator circuits for decoding codiciconvoluzionali, method for the generation of this type of circuit and
WO2002060919A2 (en) 2000-12-12 2002-08-08 Medimmune, Inc. Molecules with extended half-lives, compositions and uses thereof
EP1243276A1 (en) 2001-03-23 2002-09-25 Patrick Henry Beusker Elongated and multiple spacers containing activatible prodrugs
US6884869B2 (en) 2001-04-30 2005-04-26 Seattle Genetics, Inc. Pentapeptide compounds and uses related thereto
IL154183D0 (en) 2001-05-31 2003-07-31 Medarex Inc Cytotoxins, prodrugs, linkers and stabilizers useful therefor
US6441163B1 (en) 2001-05-31 2002-08-27 Immunogen, Inc. Methods for preparation of cytotoxic conjugates of maytansinoids and cell binding agents
DE60215819T2 (en) 2001-08-03 2007-09-06 Tyco Healthcare Group Lp, Norwalk Marker tissue marking device for use with a
US7317091B2 (en) 2002-03-01 2008-01-08 Xencor, Inc. Optimized Fc variants
US20060235208A1 (en) 2002-09-27 2006-10-19 Xencor, Inc. Fc variants with optimized properties
US8188231B2 (en) 2002-09-27 2012-05-29 Xencor, Inc. Optimized FC variants
US8084582B2 (en) 2003-03-03 2011-12-27 Xencor, Inc. Optimized anti-CD20 monoclonal antibodies having Fc variants
HUE027549T2 (en) 2002-07-31 2016-10-28 Seattle Genetics Inc Drug conjugates and their use for treating cancer, an autoimmune disease or an infectious disease
EP1391213A1 (en) 2002-08-21 2004-02-25 Boehringer Ingelheim International GmbH Compositions and methods for treating cancer using maytansinoid CD44 antibody immunoconjugates and chemotherapeutic agents
DK1931709T3 (en) 2005-10-03 2017-03-13 Xencor Inc Fc variants with optimized Fc receptor binding properties
DE10246870B3 (en) 2002-10-08 2004-04-29 Renk Aktiengesellschaft Electro-hydrodynamic superimposed steering
WO2004043493A1 (en) 2002-11-14 2004-05-27 Syntarga B.V. Prodrugs built as multiple self-elimination-release spacers
US7610156B2 (en) 2003-03-31 2009-10-27 Xencor, Inc. Methods for rational pegylation of proteins
US7276497B2 (en) 2003-05-20 2007-10-02 Immunogen Inc. Cytotoxic agents comprising new maytansinoids
PT1651162E (en) 2003-05-20 2016-02-22 Immunogen Inc Improved cytotoxic agents comprising new maytansinoids
SG195524A1 (en) 2003-11-06 2013-12-30 Seattle Genetics Inc Monomethylvaline compounds capable of conjugation to ligands
US7375078B2 (en) 2004-02-23 2008-05-20 Genentech, Inc. Heterocyclic self-immolative linkers and conjugates
WO2005084390A2 (en) 2004-03-02 2005-09-15 Seattle Genetics, Inc. Partially loaded antibodies and methods of their conjugation
WO2005112919A2 (en) 2004-05-19 2005-12-01 Medarex, Inc. Self-immolative linkers and drug conjugates
RU2402548C2 (en) 2004-05-19 2010-10-27 Медарекс, Инк. Chemical linkers and conjugates thereof
US7714016B2 (en) 2005-04-08 2010-05-11 Medarex, Inc. Cytotoxic compounds and conjugates with cleavable substrates
SI1791565T1 (en) 2004-09-23 2016-08-31 Genentech, Inc. Cysteine engineered antibodies and conjugates
EP2535355B1 (en) 2005-03-23 2019-01-02 Genmab A/S Antibodies against CD38 for treatment of multiple myeloma
CA2605507C (en) 2005-04-19 2016-06-28 Seattle Genetics, Inc. Humanized anti-cd70 binding agents and uses thereof
AR053489A1 (en) * 2005-05-24 2007-05-09 Morphosys Ag profile generation therapeutic antibodies fully human HuCAL gold derivatives specific for human CD38
DK1912671T3 (en) 2005-07-18 2017-11-27 Seattle Genetics Inc Beta-glucuronide linker-drug conjugates
EP1909846B1 (en) 2005-08-05 2018-12-26 Syntarga B.V. Triazole-containing releasable linkers, conjugates comprising the same and processes for their preparation
US8088896B2 (en) * 2005-10-12 2012-01-03 Morphosys Ag Generation and profiling of fully human gold-derived therapeutic antibodies specific for human CD38
US7847105B2 (en) 2005-10-26 2010-12-07 Medarex, Inc. Methods and compounds for preparing CC-1065 analogs
CA2627190A1 (en) 2005-11-10 2007-05-24 Medarex, Inc. Duocarmycin derivatives as novel cytotoxic compounds and conjugates
EP1994000B1 (en) 2006-02-02 2017-08-23 Syntarga B.V. Water-soluble cc-1065 analogs and their conjugates
AU2007302448C1 (en) 2006-09-26 2019-02-14 Genmab A/S Combination treatment of CD38-expressing tumors
EP1914242A1 (en) 2006-10-19 2008-04-23 Sanofi-Aventis Novel anti-CD38 antibodies for the treatment of cancer
EP2173739B1 (en) 2007-08-01 2013-07-31 Syntarga B.V. Substituted cc-1065 analogs and their conjugates
US20090076249A1 (en) 2007-09-19 2009-03-19 Michel De Weers Antibodies against CD38 for treatment of multiple myeloma
KR101499278B1 (en) * 2007-12-17 2015-03-06 화이자 리미티드 Treatment of interstitial cystitis
CN102264391A (en) * 2008-08-20 2011-11-30 森托科尔奥索生物科技公司 Il 13-engineered anti-antibodies, compositions, methods and uses
PL2344478T3 (en) 2008-11-03 2018-02-28 Syntarga B.V. Cc-1065 analogs and their conjugates
JP5725508B2 (en) 2009-03-25 2015-05-27 国立大学法人東北大学 Lh type bispecific antibody
TWI564304B (en) 2010-12-30 2017-01-01 Takeda Pharmaceuticals Co Anti-cd38 antibodies

Also Published As

Publication number Publication date
HRP20181245T1 (en) 2018-10-05
KR20190015764A (en) 2019-02-14
JP6148984B2 (en) 2017-06-14
CN103282383A (en) 2013-09-04
TWI564304B (en) 2017-01-01
NZ705848A (en) 2016-07-29
TW201247705A (en) 2012-12-01
SI2658871T1 (en) 2018-11-30
WO2012092616A1 (en) 2012-07-05
ES2674175T3 (en) 2018-06-27
JP6425644B2 (en) 2018-11-21
HUE038727T2 (en) 2018-11-28
EA201390993A1 (en) 2013-12-30
PL2658871T3 (en) 2018-11-30
JP6425635B2 (en) 2018-11-21
EP2658870B1 (en) 2018-04-25
US20130171154A1 (en) 2013-07-04
RS57526B1 (en) 2018-10-31
SI2658870T1 (en) 2018-10-30
ES2690095T3 (en) 2018-11-19
US20180066069A1 (en) 2018-03-08
JP2018019689A (en) 2018-02-08
EP2658871A1 (en) 2013-11-06
AU2011351921A1 (en) 2013-07-11
EA029303B1 (en) 2018-03-30
EP2658871B1 (en) 2018-05-02
SG191211A1 (en) 2013-07-31
CA2822061A1 (en) 2012-07-05
EP2658870A1 (en) 2013-11-06
CN103282383B (en) 2017-08-29
LT2658870T (en) 2018-09-10
BR112013017009A2 (en) 2017-07-25
US20140155584A1 (en) 2014-06-05
US20150203587A1 (en) 2015-07-23
JP2016121139A (en) 2016-07-07
JP2014509187A (en) 2014-04-17
DK2658871T3 (en) 2018-08-13
US8926969B2 (en) 2015-01-06
KR101945002B1 (en) 2019-02-07
CR20130313A (en) 2013-08-09
EP3284755A1 (en) 2018-02-21
KR20140032963A (en) 2014-03-17
IL226973A (en) 2016-08-31
TR201808709T4 (en) 2018-07-23
AU2017204571A1 (en) 2017-07-27
JP2018029581A (en) 2018-03-01
GEP20166493B (en) 2016-06-27
DK2658870T3 (en) 2018-08-06
CN107365385A (en) 2017-11-21
US9790285B2 (en) 2017-10-17
AR084747A1 (en) 2013-06-05
ECSP13012794A (en) 2013-10-31
ZA201304696B (en) 2014-09-25
CO6761368A2 (en) 2013-09-30
US8362211B2 (en) 2013-01-29
WO2012092612A1 (en) 2012-07-05
MX2013007455A (en) 2013-07-22
HRP20181176T1 (en) 2018-09-21
RS57494B1 (en) 2018-10-31
EP3284754A1 (en) 2018-02-21
PL2658870T3 (en) 2018-11-30
US20150291702A1 (en) 2015-10-15
EA201791186A1 (en) 2017-10-31
JP2014509837A (en) 2014-04-24
LT2658871T (en) 2018-09-10
MA34763B1 (en) 2013-12-03
NZ612272A (en) 2015-04-24
HUE038535T2 (en) 2018-10-29
AU2011351921B2 (en) 2017-04-13
MY160499A (en) 2017-03-15
US20120201827A1 (en) 2012-08-09
UY33850A (en) 2012-07-31
MX350903B (en) 2017-09-25
JP5843884B2 (en) 2016-01-13
JP2016034954A (en) 2016-03-17
US20180016349A1 (en) 2018-01-18
US9676869B2 (en) 2017-06-13
US9102744B2 (en) 2015-08-11

Similar Documents

Publication Publication Date Title
ES2527961T3 (en) human monoclonal antibodies to CD70
PE17222014A1 (en) Anti-pd-l1 and its use to improve T cell function
AR077111A1 (en) tetravalent bispecific protein antigen-binding
JP2015535691A5 (en)
CR10298A (en) Methods and compositions for antagonizing rage
MXPA04008870A (en) ANTI-alphav.
CL2017001580A1 (en) Antibody or antibody fragment against CD38 humanized antibody, antibody conjugate with a cytotoxic compound pharmaceutical composition with said antibodies using the antibodies to treat cancer or autoimmune disease to diagnose cancer polynucleotide method vector and host cell.
RU2010129045A (en) Binding molecules to human receptor oh40
AR087615A1 (en) Bispecific molecules antigen-binding
CY1118369T1 (en) Cd38 antibodies to treat MULTIPLE MYELOMA
GT200900248A (en) "Binding proteins, including antibodies, antibody derivatives and antibody fragments which specifically bind CD154 and its uses"
TW201843170A (en) The humanized anti - factor antibodies and uses d
EA201201435A1 (en) Heterodimer ANTIBODY-Fc-containing proteins and methods of making
UY33728A (en) ? SILENT Fc variants of anti-CD40 ?.
RU2010115886A (en) Cd19-linking agents and their use
GEP20074222B (en) Antibodies to cd40
EA201201533A1 (en) Prlr-specific antibody and its application
UA119167C2 (en) Bispecific antibodies that bind to cd38 and cd3
ECSP13012794A (en) Anti-CD38 antibodies
UA111818C2 (en) Antibodies against csf-1r
RU2010107175A (en) human antibodies to human cd20 and their method of use
PE09252005A1 (en) humanized recombinant anti-interleukin 10
AR080501A1 (en) Antigenic determinant anti programmed death 1 (anti-pd1)
NZ595235A (en) Compositions and methods for increasing muscle growth
PE05802013A1 (en) therapeutical DLL4 binding proteins

Legal Events

Date Code Title Description
FG Grant, registration